Intro

The chapter delves into the FDA's fast track approval of Amgen's lung cancer therapy, Sotoresab, and the implications of a study comparing high and low doses, revealing minimal efficacy gains with higher dosage but increased side effects, leading to safety and financial concerns.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app